Repository logo
 

B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Zouggari, Yasmine 
Ait-Oufella, Hafid 
Bonnin, Philippe 
Simon, Tabassome 
Sage, Andrew P 

Abstract

Acute myocardial infarction is a severe ischemic disease responsible for heart failure and sudden death. Here, we show that after acute myocardial infarction in mice, mature B lymphocytes selectively produce Ccl7 and induce Ly6C(hi) monocyte mobilization and recruitment to the heart, leading to enhanced tissue injury and deterioration of myocardial function. Genetic (Baff receptor deficiency) or antibody-mediated (CD20- or Baff-specific antibody) depletion of mature B lymphocytes impeded Ccl7 production and monocyte mobilization, limited myocardial injury and improved heart function. These effects were recapitulated in mice with B cell-selective Ccl7 deficiency. We also show that high circulating concentrations of CCL7 and BAFF in patients with acute myocardial infarction predict increased risk of death or recurrent myocardial infarction. This work identifies a crucial interaction between mature B lymphocytes and monocytes after acute myocardial ischemia and identifies new therapeutic targets for acute myocardial infarction.

Description

Keywords

Animals, B-Cell Activating Factor, B-Lymphocytes, Chemokine CCL7, Heart, Humans, Lymphocyte Depletion, Mice, Monocytes, Myocardial Infarction, Signal Transduction

Journal Title

Nat Med

Conference Name

Journal ISSN

1078-8956
1546-170X

Volume Title

19

Publisher

Springer Science and Business Media LLC
Sponsorship
British Heart Foundation (None)
This work was supported by Inserm, British Heart Foundation (Z.M.), European Research Council (Z.M.), Fondation Coeur et Recherche (Z.M., T.S., N.D.), Fondation pour la Recherche Medicale (J.S.S.), European Union Seven Framework programme TOLERAGE (Z.M.), Fondation Leducq transatlantic network (C.J.B., D.T., A.T., J.S.S., Z.M.), National Institutes of Health grants AI56363 and AI057157, and a grant from The Lymphoma Research Foundation (T.F.T).